TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Moderate to severe prosthetic valve regurgitation (PVR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Patellar redislocation rate
Endpoint domain: Mortality/survival
Primary endpoint: Identification of key message on mortality
Endpoint domain: Mortality/survival
Primary endpoint: Overall time required
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tissue peak concentration after administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Irisin concentration results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: hemoglobin content one day after operation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: hemoglobin content 7 days after operation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: total red blood cell loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Forced Expiratory Volume in one second (FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Diffusion Capacity for Carbon Monoxide (DLco)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: combined symptom medication score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MPA AUC(12) values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total RMS wavefront error
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change of direction (CoD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: jumping ability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in pain from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vibration perception threshold (VPT) for left foot
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Neonatal mortality rate beyond the first 24 hours
Endpoint domain: Mortality/survival
Primary endpoint: Mean reduction in HBV DNA level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Attempts to quit smoking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of microbiologically documented infections
Endpoint domain: Adverse events/effects
Primary endpoint: Need for rehospitalizations for infectious events
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: stroke/systemic embolism, major bleeding, or death
Endpoint domain: Mortality/survival
Primary endpoint: Child conduct problems
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: anatomical cure rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Failed inhibition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Error signal increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Phasic alertness increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CAC progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: TR levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Development of VTE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Haemorrhagic complications
Endpoint domain: Adverse events/effects
Primary endpoint: Total annual drug expenditure
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Proximal migration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: neuropsychological rehabilitation outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Infection rate of 7-month newborns
Endpoint domain: Adverse events/effects
Primary endpoint: C levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: E level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: negative rate of HBV DNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: negative rate of HBeAg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: positive rate of HBeAb
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Transition from UTI to Asymptomatic Bacteriuria
Endpoint domain: Adverse events/effects
Primary endpoint: relative change in lung function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Diagnostic yield for SCE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success rate of optimal intubation conditions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of significant hypotension requiring vasopressor treatment
Endpoint domain: Adverse events/effects
Primary endpoint: oxygen saturation decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: pulse rate decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: cumulative WBA Δlog cfu
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: 1-year hospitalization rate
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: 2-year hospitalization rate
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: CR-neoplasia rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: CR-IM rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Stenosis rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endothelial inflammatory response (IL-6, IL-10, sICAM-1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: drop out rate
Endpoint domain: Adverse events/effects
Primary endpoint: treatment response
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Normalization of 25OHD concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: greater abstinence during follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduced use of cigarettes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: greater craving relief and satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: hip flexion range of motion (ROM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful insertion of ILMA at the first attempt
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Enhancement of student's knowledge
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Enhancement of student's attitudes
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Enhancement of communication patterns
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Enhancement of behavioral intentions
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: performance in patient education
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of confluent mucositis
Endpoint domain: Adverse events/effects
Primary endpoint: Mortality due to pulmonary embolism
Endpoint domain: Mortality/survival
Primary endpoint: Micro push-out bond strengths
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endurance time in hypobaria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal voluntary contraction (MVC) force
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decrease in lymphedema
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of temporary cranial nerve injuries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: NME disability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Flexion/extension ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: survival benefits
Endpoint domain: Mortality/survival
Primary endpoint: Force applied during tissue palpation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tissue consistency interpretation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participant confidence in assessments
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: sleep quality factor score
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: global PSQI score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: sleep efficiency factor score
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Drop in blood pressure
Endpoint domain: Adverse events/effects
Primary endpoint: Drop in oxygen saturation
Endpoint domain: Adverse events/effects
Primary endpoint: T1 relaxation time of blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum FEV(1) response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Methacholine PC(20) improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Cortisol suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Return to work rates
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Costs for days on sick leave
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: COPM-S score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Mean transepidermal water loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Rilpivirine RAMs detection rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Etravirine RAMs detection rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resistance to emtricitabine, tenofovir, and rilpivirine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hypoventilation index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: sleeping parameters (time and rate of sleep at stage I and II)
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: 10-month mortality
Endpoint domain: Mortality/survival
Primary endpoint: development of heart failure at 30 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: CD4+ lymphocyte counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mean increase in IOP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Sustained smoking abstinence rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reproducibility of tumor measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inter-observer agreement for tumor conspicuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inter-observer agreement for edge sharpness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: recurrence of atypical polyps
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: degree of angina
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: degree of dyspnea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: detection of mediastinal or lung parenchymal abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: blood hemoglobin value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: CA125 value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Reduction in prevalence of musculoskeletal pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: PGA of 0/1 at week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PASI 75 response at week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of PPV in preventing CAP
Endpoint domain: Mortality/survival
Primary endpoint: mean increases in high-density lipoprotein (HDL) cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: mean decreases in calculated low-density lipoprotein (LDL)/HDL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: mean increases in total triglycerides
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: median reduction in pain score with movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: odds of experiencing adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: median time from initial delivery of analgesia to leaving department
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: number of words recalled in immediate and delayed recall
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Time to first analgesia requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of LANSS pain scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SNAQ scores
Endpoint domain: Life impact
Endpoint subdomain: Appetite loss
Primary endpoint: Incremental Cost-Effectiveness Ratio (ICER) per kilogram of weight loss
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: permeability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patients IOWA satisfaction score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: need for catecholamines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: reperfusion‐induced tissue injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical response at end of treatment (EOT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptomatic status of tibioperoneal lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Limb amputation
Endpoint domain: Adverse events/effects
Primary endpoint: Relative change in FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Sputum P aeruginosa density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Respiratory Domain of the CFQ‐R
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Walking time increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Moderate-to-vigorous physical activity increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in mean ambulatory SBP and DBP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Ambulatory BP response rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean morning VAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean evening VAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean DRI values
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Proportion of doses prepared correctly
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chromium concentrations in patient plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient-reported outcome measures (PROM) improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rate of LMF development at the ankle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perception of fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Rate of memory retention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: prothrombin time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: post-transplant hospital stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Proportion of responders within the first 45 minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Cortisol metabolic ratio (MR) inhibition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Reduction in exacerbations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in severity of symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of vegetable preparations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Variety of vegetables used
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: App usage increase
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Disease-related mortality
Endpoint domain: Mortality/survival
Primary endpoint: Deep surgical-site infections
Endpoint domain: Adverse events/effects
Primary endpoint: Total effective radiation dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum levels of IL-6, IL-8, and TNF-alpha
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of patients halving visual angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average lines of visual acuity gained
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to maximum concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: maximum concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Clinically tumor free after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Survival benefit
Endpoint domain: Mortality/survival
Primary endpoint: postoperative pain-free duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pain scores 1 day after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: significant hypotension
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of grade 3-5 chemotherapy toxicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Adverse events/effects
Primary endpoint: Severity score using SSS‐JDA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective evaluation using Pt‐VAS
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Serum TARC levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Surgical site infection (SWI) incidence
Endpoint domain: Adverse events/effects
Primary endpoint: PCR corrected cure rates at day 28
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Re-infection rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weight gain (>or=7%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: internal adaptation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of at least 50% in Hamilton Depression Rating Scale scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Discontinuation of treatment prematurely
Endpoint domain: Adverse events/effects
Primary endpoint: Adverse events resulting in termination
Endpoint domain: Adverse events/effects
Primary endpoint: Post-anesthesia care unit (PACU) recovery time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Platelet function analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Physical health composite score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Mental health composite score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: local skeletal muscle TNF-alpha expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: local iNOS expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Compliance with behavioral treatments and follow-up appointments
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Satisfaction with role and training
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Angiogenesis promotion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 3- and 5-year survival
Endpoint domain: Mortality/survival
Primary endpoint: Asthma control maintenance at week 8
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in ACQ score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes